What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?
17 analysts have issued 1-year target prices for Intercept Pharmaceuticals' shares. Their forecasts range from $60.00 to $350.00. On average, they expect Intercept Pharmaceuticals' share price to reach $187.12 in the next twelve months.
When will Intercept Pharmaceuticals announce their earnings?
Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
What are analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
Cantor Fitzgerald analysts commented, "With concerns in Nov. 2016 to achieve REGENERATE interim enrollment by 1H17, Intercept amended protocols and now expects completion by mid-2017." (2/13/2017)
- Wedbush analysts commented, "Intercept announced two protocol amendments to the Phase 3 REGENERATE trial including updating the definition of NASH resolution to the newer objective definition and only requiring statistical significance of one of the two components (NASH resolution without worsening of fibrosis and improvement in fibrosis without worsening of NASH) making up the co-primary endpoint in the ITT patient population. The previous definition of NASH resolution was the absence (score of zero) of at least one of the three components of NASH (steatosis, ballooning, or inflammation; Gastroenterology 2016; 150:1147-59) to the absence of ballooning (score to zero from 0-2) and residual (score of 1) or no (score of 0) inflammation (from 0-3). The new objective definition of NASH resolution is in-line with Genfit's ongoing Phase 3 NASH trial (March 10, 2016 press release)." (2/8/2017)
According to Zacks Investment Research, "Intercept received a major boost with the approval of its lead drug, Ocaliva, in combination with ursodeoxycholic acid (UDCA), for the treatment of primary biliary cholangitis (PBC) in both the U.S. and the EU. Successful commercialization of the drug will significantly boost the company’s revenues, going forward. The PBC market holds strong potential. We are also encouraged by Intercept’s efforts to develop the drug in additional indications. Loss estimates have narrowed lately ahead of the company’s Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters. Moreover, the company’s share price outperformed the industry in the last twelve months. However, expenses will continue to rise in the coming quarters as the company prepares for a potential launch of Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline." (1/19/2017)
FBR & Co analysts commented, "At the annual meeting of the AASLD (American Association for the Study of Liver Diseases) held in Boston, Massachusetts, November 11–15, Intercept Pharmaceuticals and its collaborators presented results from three post-hoc analyses of the completed POISE Phase III trial with Ocaliva in patients with primary biliary cholangitis (PBC). In parsing through the analyses presented, we came away with a more definitive picture of the wealth of data generated by POISE, which is the pivotal trial that gained Ocaliva FDA approval in May 2016. Importantly, the analyses provide data that may be added to the compendium of information that supports Ocaliva’s nascent potential in PBC." (11/18/2016)
Oppenheimer Holdings, Inc. analysts commented, "We believe the review extension and clock stoppage are a routine part of the engagement between the sponsor and the regulatory agency in Europe. We continue to expect Radius to sign an EU partnership for abaloparatide-SC prior to approval. Importantly, we do believe that abaloparatide is meaningfully differentiated from Forteo, which should help the product compete in ex-US markets. Transdermal data expected mid-2016, significant potential We continue to expect positive human replicative bioequivalence data mid-16 and believe the transdermal patch could dramatically expand the duration and magnitude of revenues." (6/1/2016)
Who owns Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Orbimed Advisors LLC (4.51%), State Street Corp (3.03%), Marshall Wace LLP (0.41%), White Square Capital LLP (0.26%) and National Planning Corp (0.21%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, David Shapiro, Jonathan Silverstein, Klaus R Dr Veitinger, Lisa Bright, Luciano Adorini, Mark Pruzanski, Nicole Williams, Orbimed Advisors Llc and Rachel Mcminn.
Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Credit Agricole S A, Metropolitan Life Insurance Co. NY, Van ECK Associates Corp, First Republic Investment Management Inc., Federated Investors Inc. PA and Guggenheim Capital LLC. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, David Shapiro, Lisa Bright, Mark Pruzanski and Rachel Mcminn.
Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, White Square Capital LLP, ING Groep NV, FMR LLC, A.R.T. Advisors LLC, State Board of Administration of Florida Retirement System and Ladenburg Thalmann Financial Services Inc..
How do I buy Intercept Pharmaceuticals stock?
Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Intercept Pharmaceuticals stock cost?
One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $128.45.